Polpharma Biologics Group’s joint venture has entered into an agreement with Teva to commercialise a biosimilar drug to Ranibizumab. The biologic drug is used in ophthalmic therapy. A partnership agreement between Teva and a joint venture with Santo Holding (Strungmann Group) of Polpharma Biologics Group will see the commercialisation of the biosimilar drug Ranibizumab (Lucentis)….
Polpharma Biologics and global generic giant Sandoz will jointly launch a biosimilar to the multiple sclerosis (SM) biological drug. This is the result of a contract signed last Tuesday for the commercialisation of the product. Polpharma will fight for a billion-dollar market Polpharma is developing a biosimilar to the Tysabri drug (natalizumab) produced by Biogen…
Mabion, a Polish biotechnology company, announced that it will start developing three new biosimilar drugs in the second half of 2019. However, the company will inform about the applications of the drugs only at the moment of starting work on them. In total, the company has qualified research projects into three groups. The first is…
Polfarmex has invested in a new packaging line, which has appeared at its production plant in Kutno. Thanks to the new blister machine, the production of blister packs will be able to increase by around 60%, while the new unit cartoning machine will enable the efficiency of the packaging process for medicinal products to be…
By 2023, Samsung will invest as much as $205bn in its pharmaceutical, biopharmaceutical, semiconductor and telecommunications industries. This investment is intended to support the company’s further growth and biosimilar drug production ventures by Samsung Bioepis and its Samsung Biologic contract manufacturing unit, which recently began producing Moderna’s COVID-19 vaccine. The company’s activities are aimed at…
The US Food and Drug Administration (FDA) grants expedited approval to Biogen to market its Alzheimer’s drug in the US. The drug in question is Aducanumab, also known as Aduhelm, which is the first Alzheimer’s drug approved since 2003. Biogen’s drug for Alzheimer’s is a breakthrough in medicine The US Food and Drug Administration (FDA) approved…
Neuca is not slowing down and is making another acquisition in the area of clinical trials. This time, it is the MTZ Clinical Research centre, specialising in early phase clinical research projects. This is the first centre of its kind in the Pratia network, belonging to Neuca Group, and, as it was announced, the first…
Paulina Romaniszyn was appointed as Country Head and General Manager in the Polish branch of Stada. The new Head will use the experience she has gained previously and take care of the implementation of the adopted development strategy. Experience of Romaniszyn in pharmaceutical companies Paulina Romaniszyn became the new head of the Polish branch of…
Johnson & Johnson announced that it has entered into an agreement to purchase Momenta Pharmaceuticals, a manufacturer of drugs for autoimmune diseases. This is one of the largest transaction on the pharmaceutical market this year. Finalisation of the transaction in 2020 Under the terms of the transaction, which have been approved by the boards of…
According to forecasts presented in the PMR report “Biological and biosimilar drugs market in Poland 2019. Market analysis and development forecasts for 2019-2024”, the market of reference biological drugs in Poland is growing much slower than that of biosimilar products. In 2018 it reached a growth rate of 3%, compared to 40% in the market…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.